Cohen Kzia, Paz Ehud
Palliative Care Service, Emek Medical Center. Afula, Israel.
Intensive Care and Palliative Care, PC Service, Emek Medical Center. Afula, Israel.
Harefuah. 2022 May;161(5):304-310.
This study examined PPS (Palliative Performance Scale) use as a tool estimating life expectancy in patients with various life-threatening diseases who required palliative consultation during hospitalization in an acute regional hospital in northern Israel.
Prognostication is the ability to evaluate outcome and expected course of a medical condition based on knowledge and experience. Special emphasis is given to the prediction of life expectancy in end-of-life situations, as prognosis directs the treatment approach, the policy regarding tests and procedures, and discharge planning. Research mentions two main methods for assessing life expectancy: one is CPS - Clinician's Prediction of Survival and the other is AES - Actuarial Estimation of Survival based on test results, statistics and clinical tools. Since physical status correlates well with survival, it is included in most prognostication tools.
A retrospective study for the period January 2015-September 2018 examined the records of patients assessed by the Palliative Consult Team (PCT), using PPS. Variables were initial PPS score, age, gender, ethnic origin, diagnosis and survival time. Patients were monitored six months from initial assessment.
A total of 588 patients' records assessed by PCT using PPS, were included in the study. Findings showed PPS to be a significant predictor of survival for all research groups, with no ethnic differences. In the current study population, differences were found between varied diagnoses in life expectancy and functional status. It also became clear that life expectancy of most subjects with a functional status of PPS-40 and below did not exceed six months.
This research strengthens the link between functional status and life expectancy and is the first in Israel to support the use of the PPS tool as part of the prognostication process in patients with a variety of incurable diseases. The presentation of findings in survival ranges according to the value of PPS is unique to this study and its ability to assist medical staff both in making clinical decisions and in choosing the appropriate terminology for the sensitive and complex procedure of delivering a prognosis to a patient and loved ones.
本研究考察了姑息治疗表现量表(Palliative Performance Scale,PPS)作为一种工具,用于评估以色列北部一家急性地区医院住院期间需要姑息治疗咨询的各种危及生命疾病患者的预期寿命。
预后判断是指基于知识和经验评估医疗状况的结果和预期病程的能力。在生命终末期的情况下,特别强调预期寿命的预测,因为预后指导治疗方法、关于检查和程序的政策以及出院计划。研究提到了两种评估预期寿命的主要方法:一种是临床医生生存预测(Clinician's Prediction of Survival,CPS),另一种是基于测试结果、统计数据和临床工具的精算生存估计(Actuarial Estimation of Survival,AES)。由于身体状况与生存密切相关,因此它被纳入了大多数预后判断工具中。
一项对2015年1月至2018年9月期间的回顾性研究,检查了由姑息治疗咨询团队(Palliative Consult Team,PCT)使用PPS评估的患者记录。变量包括初始PPS评分、年龄、性别、种族、诊断和生存时间。从初始评估开始对患者进行为期六个月的监测。
本研究纳入了PCT使用PPS评估的共588例患者记录。研究结果表明,PPS是所有研究组生存的重要预测指标,且不存在种族差异。在当前研究人群中,不同诊断在预期寿命和功能状态方面存在差异。还明确了功能状态为PPS - 40及以下的大多数受试者的预期寿命不超过六个月。
本研究加强了功能状态与预期寿命之间的联系,并且是以色列首个支持将PPS工具用作各种不治之症患者预后判断过程一部分的研究。根据PPS值按生存范围呈现研究结果是本研究独有的,其能够帮助医护人员做出临床决策,并为向患者及其亲人传达预后这一敏感而复杂的过程选择合适的术语。